Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Gets Personal: LabCorp Agreement Pairs Cancer Med With AmpliChip

This article was originally published in The Gray Sheet

Executive Summary

The pharmacy benefit manager Medco is working with the Laboratory Corporation of America to develop data on a personalized medicine approach to the use of the breast cancer drug tamoxifen

You may also be interested in...



Is Data Adequate To Support Warfarin Dosing Test Coverage? Comments Vary

Stakeholder opinions on whether Medicare should cover warfarin dosing tests vary based on the commenters' views on the adequacy of existing data

Is Data Adequate To Support Warfarin Dosing Test Coverage? Comments Vary

Stakeholder opinions on whether Medicare should cover warfarin dosing tests vary based on the commenters' views on the adequacy of existing data

Genomic Updates To Drug Labeling Could Boost Gene Testing

FDA could use results from a new research collaboration with Medco to update existing drug labeling with genomic information

Related Content

UsernamePublicRestriction

Register

MT025446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel